Literature DB >> 2948443

Pharmacokinetics of [14C]teicoplanin in male rats after single intravenous dose.

A Bernareggi, L Cavenaghi, A Assandri.   

Abstract

The pharmacokinetic profile of [14C]teicoplanin was studied in male Sprague-Dawley rats given a single 10,000-U/kg intravenous dose. The disposition of the antimicrobial activity in the body was estimated by a three-compartment open model. Plasma concentration data were fitted to a three-exponent equation. The profile of total 14C in plasma was similar to that of the microbiological activity. The cumulative recovery of total 14C 5 days after drug administration averaged 76.3% of the administered dose in the urine and 8.7% in the feces. The residual dose remaining in the animal carcasses was 11.1%. Teicoplanin was widely distributed in the body. In almost all organs, the maximum concentration of [14C]teicoplanin was already reached at the first time of killing, which was 0.25 h after the administration of drug. The liver, kidneys, skin, and fat contained most of the residual dose found in the animal carcasses 120 h after administration and behaved as a deep compartment with the adrenal glands and spleen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2948443      PMCID: PMC176523          DOI: 10.1128/AAC.30.5.733

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp.

Authors:  S Somma; L Gastaldo; A Corti
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

2.  Pharmacokinetics of teicoplanin in man after intravenous administration.

Authors:  G L Traina; M Bonati
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

3.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

5.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.

Authors:  J C Rotschafer; K Crossley; D E Zaske; K Mead; R J Sawchuk; L D Solem
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

6.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties.

Authors:  F Parenti; G Beretta; M Berti; V Arioli
Journal:  J Antibiot (Tokyo)       Date:  1978-04       Impact factor: 2.649

7.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization.

Authors:  M R Bardone; M Paternoster; C Coronelli
Journal:  J Antibiot (Tokyo)       Date:  1978-03       Impact factor: 2.649

8.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin).

Authors:  A Borghi; C Coronelli; L Faniuolo; G Allievi; R Pallanza; G G Gallo
Journal:  J Antibiot (Tokyo)       Date:  1984-06       Impact factor: 2.649

9.  Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

Authors:  R Pallanza; M Berti; B P Goldstein; E Mapelli; E Randisi; R Scotti; V Arioli
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

10.  Single-dose kinetics of intravenous vancomycin.

Authors:  D J Krogstad; R C Moellering; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

  10 in total
  9 in total

1.  Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.

Authors:  M Berti; G Candiani; M Borgonovi; P Landini; F Ripamonti; R Scotti; L Cavenaghi; M Denaro; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Pharmacokinetics of A40926 in rats after single intravenous and subcutaneous doses.

Authors:  A Bernareggi; A Danese; L Cavenaghi
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

3.  Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat.

Authors:  M Borgonovi; L A Cavenaghi; A Borghi; M Galimberti; P Kaltofen; R Merati; J E Coutant
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

4.  Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; R E Stratford; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

5.  Teicoplanin metabolism in rats.

Authors:  L F Zerilli; L Cavenaghi; A Bernareggi; A Assandri
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of teicoplanin.

Authors:  M Rowland
Journal:  Clin Pharmacokinet       Date:  1990-03       Impact factor: 6.447

Review 7.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

8.  Pharmacokinetics of individual components of teicoplanin in man.

Authors:  A Bernareggi; A Danese; A Cometti; G Buniva; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

9.  Teicoplanin metabolism in humans.

Authors:  A Bernareggi; A Borghi; M Borgonovi; L Cavenaghi; P Ferrari; K Vékey; M Zanol; L F Zerilli
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.